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Abstract
Alterations in the innate and adaptive immunity underpin psoriasis pathophysiology, with the Th17 cells subset now
recognized as the fundamental cells in the key controlling pathway involved in its pathogenesis. Since psoriasis is a
systemic disease with important comorbidity, further knowledge on the interleukin (IL)-23/Th17 axis led to the hypothesis
that there may be shared pathogenic pathways between primary skin disease and comorbidity. Psoriasis has been iden-
tified as a risk factor for cardiovascular and metabolic disease, and increasing evidence gives support to this epidemio-
logical observation from the clinical-pathologically field. As an example, increased levels of IL-23 and IL-23R have been
found in human atherosclerotic plaque, and levels correlated with symptom duration and mortality. Also, upregulation of
IL-23/IL-17 seems to play an important role in both myocardial damage and stroke, with interesting reports on deleteri-
ous effect neutralization after administration of related anti-bodies in both associated conditions. In diabetic patients,
increased levels of IL-23/IL-17 have also been observed and available data support a synergistic role of IL-23/IL-17 in
b-cells damage. In obesity, signs of an expansion of Th17 subset in adipose tissue have been reported, as well as
elevated concentrations of IL-23 in obese patients. In non-alcoholic fatty liver disease, closely related to metabolic
syndrome, but also in other mentioned cardiometabolic disorders, a predominance of IL-23 and other related pro-
inflammatory factors has been identified as participating in their pathogenesis. Thus, the involvement of the IL-23/Th17
axis in these shared psoriasis-cardiometabolic pathogenic mechanisms is reviewed and discussed in the light of the
existing preclinical and clinical evidence, including that from comorbid psoriasis patients.
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Introduction
Plaque psoriasis is a prevalent chronic, immune-mediated
inflammatory disease classically characterized by typical skin
lesions. Comorbidity is commonly present in psoriasis patients,
consistent with the systemic nature of the disease. Car-
diometabolic disease accounts for a substantial proportion of
this comorbidity to the point of psoriasis being considered an
independent risk factor for cardiovascular disease (CVD).1 Cur-
rent evidence points to the role of Th17 cells and interleukin-23
(IL-23) on this condition.1,2 Growing knowledge of its car-
diometabolic comorbidity suggests this pathway may be a link
between cutaneous and beyond-the-skin manifestations of
psoriasis.
Cytokines are core mediators enabling communication, regu-
lation and coordination between immune cells. Cytokines, along
with antigens and antigen-presenting cells (APCs) existing in the
environment, are determinant for na€ıve CD4+ cells to differenti-
ate in any of the known effector, memory or regulator subsets;
in turn, the dominant cytokine profile secreted by each subset is
responsible for their functional role.3,4
The Th17 subset was the third effector subset discovered as a
lineage of CD4+ T cells, along with the previously known Th1
and Th2 subsets.5–7 In humans, Th17 cells play a role in the
defence against extracellular bacteria and fungi8,9 and have a rec-
ognized role in development and maintenance of autoimmune
and chronic inflammatory diseases.5,10 Throughout the Th17
biologic cycle and function, a complex net of transcription
factors and mediators are involved,8–10 among which IL-23 and
IL-17A emerge as critical upstream and downstream CKs,
respectively.8
Interleukin-23 belongs to the IL-12 cytokine family, along
with IL-12 and IL-27 (involved in Th1 differentiation), and
IL-35 (involved in Treg differentiation and function). Dendritic
cells (DCs), monocytes and macrophages (i.e. APCs) from acti-
vated skin and mucosae are the main IL-23-secreting cells.11
Structurally, IL-23 is a heterodimer composed of a unique p19
subunit (IL-23p19) and a p40 subunit, common to IL-23 and
IL-12.12 IL-23 is essential in the enhancement of memory T cells,
regulation of antibody production, induction of IFN-c and pro-
liferation of Th17 cells secreting IL-17 and IL-22, contributing
to immune response against infection, but also attributed a
pathogenic role in autoimmune diseases and cancer.8,11,13 IL-23
is essential in Th17 differentiation because this CK is a strong
inducer of STAT3, which mediates signalling along with retinoic
acid orphan receptor C2 [RORC2 (RORct in mice)].2,11 Mem-
ory T cells upon activation by TGF-b and IL-6, but not na€ıve T
cells, express the IL-23 receptor, suggesting that IL-23 plays a
crucial role in Th17 expansion, survival and pathogenicity.5,7,14
Interleukin-17A, along with IL-17F and IL-22 are the effector
interleukins of Th17 cells.15 Although IL-17A is preferentially
produced by Th17 cells, they are not its exclusive source; other
cells, like monocytes, DCs, natural killer (NK) T cells,
neutrophils, innate lymphoid cells (ILCs) and cd-T cells also
secrete IL-17A. IL-17A belongs to the IL-17 cytokine family
comprising five more isoforms (A–F), indeed IL-17A and IL-17F
share similar functions.9,16,17 IL-17A is positioned as a link
between innate and adaptive immunity; it acts as an early media-
tor of the immune response at mucosal surfaces, by inducing the
production of a variety of pro-inflammatory molecules from tis-
sues and activated cells, which result in recruiting neutrophils to
tissues.9,16 Interestingly, neutrophils can secrete IL-17 them-
selves, acting as an amplifier and inducing the recruitment and
activation of additional neutrophils. Thus, neutrophils seem to
have a role not only in acute but also in chronic inflammation.12
Unlike other subsets, Th17 cells do not depend on its effector
CK IL-17 for differentiation. Rather, combinations of IL-23 plus
IL-6, IL-1b and TGF-b are required for an efficient differentia-
tion of Th17 subset (Fig. 1).9
Due to plasticity observed in CD4+ T cells, differentiation of
Th17 in the presence of IL-23 leads to tissue inflammation
because of IL-23-induced downregulation of IL-10 (involved in
Treg cells function). Conversely, differentiation and function of
Treg is mediated by TGF-b, but, in the presence of IL-6, Treg
differentiation is inhibited in favour of Th17 (Fig. 2).9
The IL-23/Th17 axis in psoriasis
Prevalence of psoriasis is estimated between 1.5% and 5% in
most developed countries; it affects approximately 125 million
people worldwide,1,18 plaque psoriasis being the most frequent
form of the disease.19 Despite the primary cause of psoriasis
being unknown, some genetic factors are acknowledged risk fac-
tors for its development.20,21 Further, a dysregulated immune
response involving keratinocytes, vascular endothelial cells,
Th17, Th1, Treg, cd-T cells, DCs, macrophages, neutrophils,
mast cells and NK cells underlies the pathogenesis of
psoriasis.19,22,23
The primary consideration of psoriasis as a Th1/Tc1-mediated
disease19,24 was supported by efficacy of monoclonal antibodies
targeting p40 subunit of IL-12, the cytokine considered crucial
in the Th1 differentiation.25 However, IL-23 identification
almost two decades ago,12 together with the fact that IL-23
shared with IL-12 the same p40 subunit, and the knowledge
acquired on the pathway IL-23/Th17 have actually changed the
paradigm.2,19,22,26
When any factor acts as a trigger on genetically predisposed
skin, the inflammatory cascade and a dysregulated interaction
between innate and adaptive immune components and cells of
the skin are initiated. Stressed keratinocytes start an innate
immune response by producing antimicrobial peptides (AMPs),
ß-defensins, cytokines and chemokines. These molecules attract
neutrophils to and activate resident mast cells in the skin, and it
is predominantly these two types of cells that contain IL-17 in
psoriasis. Also, keratinocytes release self-DNA that forms com-
plexes with cytokines and AMPs, inducing activation of DCs
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which migrate into the lymph nodes.15,27 There, derived inflam-
matory milieu results in na€ıve T cells being exposed to specific
patterns of cytokines inducing subset differentiation,28,29 thus
adding adaptive responses. Differentiated Th17 cells leave the
nodes through the skin, where they produce IL-17.22,30 Some
subsets of these activated Th17 cells, as well as other types of T
cells, are programed to remain in the skin, so that populations
of autoreactive tissue-resident cells will persist and contribute to
psoriasis pathology.31
The presence of TGF-b IL-6 and IL-1b induces initial differ-
entiation to Th17 cells and leads to upregulation of IL-23R
expression (required for IL-23 signalling).7,8,29 Then, IL-23
released by DCs and APCs can link its receptor, activating Th17
cells and contributing to their phenotype maintenance.2,22
Therefore, IL-23 plays a crucial role for expansion and survival
of the Th17 subset.7 Its role might be even more critical in
autoimmune inflammation considering that plasticity of Th17
cells may lead them to switch to a non-classical phenotype
(ex-Th17) producing IFN-c but having lost its IL-17 expression.
These cells exhibit increased survival, and more active cytokine
production are resistant to suppressive action of Treg cells and
can elude treatments targeting IL-17.32 Thus, Th17 lineage cells
or key upstream mediators of their differentiation would need to
be targeted instead.
Activated Th17 cells induce the production of the pro-
inflammatory cytokines IL-17A-F, IL-22, IL-21 and TNF-a.2
Effects of IL-17A are stimulation of neutrophils recruitment and
activation, enhancement of angiogenesis, mediation of tissue
remodelling, direct activation of keratinocytes and, synergisti-
cally with TNF-a, enhancement of inflammation.22 IL-22
induces keratinocyte hyperproliferation and AMPs secretion by
keratinocytes, is involved in tissue remodelling and its levels
have been showed to correlate with psoriasis severity.33–35 IL-21
participates in expression of IL-23R and RORct.36 TNF-a can
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Figure 1 Schematic representation of Th17 cells developmental mechanism, regulators involved and effector functions.
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increase IL-23 synthesis, which in turn enhances synthesis of
IL-17 as well as of IFN-c by memory T cells, eventually con-
tributing to perpetuation of skin inflammatory process.7,13,22
Animal studies have demonstrated that IL-23, but not IL-12,
intradermal injections induce a psoriasis-like disease in mice
with elevated transcription of IL-23/Th17-related genes.37,38 Fur-
ther, a number of studies in psoriasis patients and healthy con-
trols have shown increased levels of p40 and p19 subunits, but
not p35 subunit (the unique IL-12 subunit), and IFN-c in psori-
atic lesions, compared with adjacent non-lesioned or healthy
skin.39–41 These findings may suggest that most of the pro-
inflammatory role attributed to IL-12 would really arise from
IL-23. Histochemical studies also suggest that psoriatic ker-
atinocytes could contribute to skin inflammation by secreting
sufficient IL-23 to amplify memory T-cell-produced IFN-c.39
Additionally, genetic studies have demonstrated associations
between genes IL23A (encoding the IL-23p19 subunit), IL23B
(encoding the IL-12/23p40 subunit), and IL23R (encoding the
IL-23R subunit), but not IL12A (encoding the IL12p35 subunit),
and the presence of psoriasis.42
Not only cytokines and related molecules increased in psori-
atic lesions but the result of lacking them, have been investi-
gated. Deficiency in p40 results in a great decrease in plaque
formation and markers of inflammation, according to results
from animal studies. When the effect of lacking p35 or p19 sub-
units was studied separately, results showed the development
of more severe or milder inflammation, respectively, than
controls.43
All these findings highlight the divergent roles of IL-12 and
IL-23 in psoriasis and consistently (i) point to the involvement
of IL-12 in pro-inflammatory effects might be lower than
classically believed and independent of IFN-c, and (ii)
strengthen the predominant role of the IL-23/Th17 axis in the
current pathogenic model of psoriasis.
Psoriasis and cardiovascular diseases: what is the
place for the IL-23/Th17 axis?
Overview
Psoriasis is a disorder affecting, but not limited to, the skin.
Thus, cardiac, metabolic, gastrointestinal, pulmonary and kidney
disease, as well as malignancies, infections, or psychiatric disor-
ders are associated conditions with variable incidence in psoria-
sis, which increase the disease burden and the mortality risk,
particularly in severe psoriasis.1
Cardiovascular disease deserves special mention in psoriasis,
as per results reported in large-scale epidemiological studies.
CVD constitutes the first or second cause of mortality (after
malignancies) among psoriasis patients,44–46 and the risk is
higher among severe patients.44,45 Duration has also been associ-
ated with CVD risk.1,47 In terms of excess mortality, CVD was
attributed globally an excess rate of 1.44 (95% CI: 1.43–1.45) per
1000 person-years;46 in absolute terms CVD is the main driver
of excess mortality in psoriasis.45 Consistent with these findings,
psoriasis patients are at higher risk of cardiovascular events, in
particular those with severe disease (RR to general population
ranged 1.70–3.04; 1.38–1.59; and 1.37–1.39, for myocardial
infarction, stroke and CV mortality, respectively).48–50 These
data support the hypothesis of psoriasis as an independent factor
for CV events. In this regard, severe psoriasis was found to con-
fer an additional 6.2% absolute risk of a 10-year rate of CV
events compared with the general population.51 Indeed, a study
Suppression on
T effector cells
Host defense,
inflammation
Th17Treg
IL-25
IFNγ
IL-4
IL-27
IL-10
TGF-β TGF-β
IL-6
IL-17
IL-22
GM-CSF
Chemokines
Retinoid acid
IL-2
IL-23
Th17Treg Th17Treg
IL-6
IL-21
IL-23R
IL-10
TGF-β
Figure 2 Schematic representation of Treg and Th17 cells regulation, stimulator and inhibitor molecules involved in development and
ultimate effector action of each pathway.
© 2020 The Authors. Journal of the European Academy of Dermatology and Venereology published by John Wiley & Sons Ltd
on behalf of European Academy of Dermatology and Venereology
JEADV 2020, 34, 1695–1706
1698 Egeberg et al.
showed that a high percentage of patients at low or intermediate
CV risk according to Framingham score must be reclassified as
intermediate and high risk, respectively, when psoriasis was
added as a scoring factor.52
These epidemiological data are consistent with findings about
abnormalities in lipid profiles of psoriasis patients. An abnormal
lipid pattern consisting of higher cholesterol concentrations in
the very low-density lipoproteins (LDL) and high-density
lipoproteins (HDL) fractions as well as higher levels of Apo A1
have been demonstrated at the onset of disease. This suggests
psoriasis predisposition to lipid abnormalities, and hypothesizes
a detrimental role of HDL-c and Apo A1 caused by oxidative
modifications.53 Of note, features of oxidative stress and impair-
ment of the antioxidant system have been evidenced in psoria-
sis.54–56 Levels of lipoprotein(a) [Lp(a)] have been reported to
be increased in psoriasis and positively correlated with markers
of oxidative stress and negatively with markers of antioxidant
activity.55,57 Significantly lower levels of HDL-c, and higher
levels of total cholesterol, LDL cholesterol and/or triglycerides
(TG) have been reported too.54,57 Both lipid abnormalities and
oxidative stress have been suggested to act along with inflamma-
tion in psoriasis to eventually induce atherosclerosis and increase
the CVR in these patients.58,59
Despite pathogenic links between psoriasis and CVD warrant-
ing further investigation, growing evidence shows the role of
chronic inflammation and immune dysfunction, so that both
could share some dysregulated pathways, such as increased
oxidative stress, monocyte and neutrophil modulation, endothe-
lial dysfunction and IL-23/Th17 signalling (Fig. 3).1 In line with
this, it has been proposed that psoriasis and atherosclerosis
would share immunological mechanisms involving IL-12/Th1
and IL-23/Th17 pathways, leading either to the plaque growth
promoted by TNF-a and IFN-c from differentiated Th1, or to
the plaque vulnerability caused by intraplaque angioneogenesis
and haemorrhage, promoted by Th17 effector CKs. Further, Th1
and Th17 proliferation would be favoured by a decrease in Treg
number and function, with subsequent lower levels of TGF-b
and IL-10, both associated with anti-inflammatory and CV pro-
tective effects.60
Several animal studies with either psoriasis or atherosclerosis
models have found the IL-23/Th17 axis to link psoriasis and vas-
cular damage and dysfunction. Studies with mice overexpressing
IL-17A in keratinocytes and mimicking many hallmark skin fea-
tures of severe psoriasis in humans, have demonstrated that
alterations of IL-17A and related downstream cytokines drove
not only cutaneous but vascular inflammatory changes
[increased reactive oxygen species (ROS) formation, oxidative
stress, endothelial dysfunction, arterial hypertension and prema-
ture death].61,62 Evidence from upstream cytokines have been
reported as well. In models of atherosclerosis, an increase in
IL-23 secretion induced by the granulocyte-macrophage colo-
ny-stimulating factor (GM-CSF) has been shown to promote
plaque instability by both increasing macrophages and DCs sus-
ceptibility to apoptosis and downregulating Bcl-2, which triggers
Th1 and Th17 responses and releases ROS.63 In patients with
atherosclerosis, IL-23 and IL23R were increased in atheroscle-
rotic plaques, compared with non-affected vessels and higher
levels of IL-23 that were observed in patients with more recent
symptoms. Moreover, long-term outcomes showed an adjusted
association between higher IL-23 plasma levels and mortality.64
Of note, blocking IL-12 by vaccination reduced atherogenesis;
however, involvement of IL-23 in the effect could not be distin-
guished, because an anti-p40 antibody was used.65
The beneficial effect of antibody treatment on both skin and
CV outcomes is a promising line of investigation already yield-
ing positive findings. As an example, antibodies targeting IL-12/
23p40, IL-23p19 and IL-17A/RA were administered to murine
models of psoriasis developing CVD in response to systemic
inflammation in a recent study. Treatment attenuated acanthosis
in correlation with lengthening time to occlusive thrombus for-
mation (with similar results to those from wild-type controls),
supports a common pathogenic pathway for both conditions.66
Coronary artery disease
Coronary artery disease (CAD) has been showed to have higher
prevalence among psoriasis patients. Myocardial infarction (MI)
may be the first manifestation of CAD, and its risk may be
increased up to threefold, compared with non-psoriatic con-
trols.67–69 Interestingly, higher prevalence of psoriasis among
CAD patients has also been reported.70
Certain polymorphisms of the human gene IL-23 R have been
associated with the risk and severity of atherosclerosis.71,72 Inves-
tigations on myocardial injury, hypertrophy and remodelling
mechanisms are providing growing knowledge on the role of the
Th17 pathway. In murine models of MI, Avalos et al. found
increased post-MI levels of IL-6, IL-23 and TGF-b mRNA in the
left ventricle. Surprisingly, levels of IL-17A mRNA were not
increased in the whole LV but only in the infarcted region, sug-
gesting a role in the ventricular remodelling after MI.73
Remodelling, responsible for ventricular dysfunction and
heart failure frequently developed after MI, is characterized by
dilation and fibrosis phenomena in the myocardium and related
to immune response after myocardial damage.74–76 Several stud-
ies addressing the potential role played by IL-23 have showed a
deleterious effect on MI models. Yan et al. demonstrated that
IL-23 rapidly increases after MI up to 3 days, whilst IL-23R and
IL-17A upregulate progressively up to 7 days, and IL-17R
remains elevated until 14 days. The deficiency of IL-23, IL-17A
and cdT cells resulted in a protective effect in mice, with higher
survival after MI, less enlargement and less severe dysfunction of
the LV, compared with wild-type controls. Thus, IL-23 from
macrophages and neutrophils would act as an indispensable
upstream regulator of IL-17A, driving its production from cdT
cells. Recruitment of cdT cells would also be favoured by IL-23,
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whilst IL-17A would promote neutrophil infiltration and fibrosis
in myocardial tissue. These changes were evident from day 7
after MI, suggesting these mechanisms are crucial in remod-
elling.75 Additional studies with animal models of ischaemia/
reperfusion injury consistently showed increases of IL-23 in the
injured myocardium. IL-23 upregulation was also associated
with enlargement of infarct size, high levels of typical biomarkers
of myocardial damage (LDH and CK), pro-inflammatory
responses (with increase of IL-17A, IL-6 and TNF-a releasing)
and pro-apoptotic effects (higher apoptotic index and lower Bcl-
2/Bax ratio). Through activation of JAK2/STAT3, IL-23 induces
secretion of IL-17A, which eventually reinforces the inflamma-
tory response and myocardial damage.77,78 Importantly, neutral-
ization of IL-23 by administration of anti-IL-23p19 antibodies
significantly reduced IL-17A levels and ischaemia/reperfusion
injury.77,79
The inflammatory hypothesis of atherothrombosis has been
present in the medical and research community for the last
decade. In the field of rheumatology disease, this has led to
explore a potential cardioprotective effect of biologic treatments
targeting these inflammation pathways in psoriasis patients.80–82
Despite results from these retrospective studies being consistent
with the overlapping mechanisms underlying both psoriasis
and CVD, no studies to date have been conducted to
prospectively assess the potential benefit of biologic therapy in
psoriasis-CVD patients. Nevertheless, the inflammatory hypoth-
esis has been tested prospectively in two large randomized clini-
cal trials involving around 25 000 CVD patients. The CANTOS
study demonstrated the benefit of targeting IL-1b to reduce CV
events,83 whilst the CIRT study did not find this positive
effect.84
Cerebrovascular disease
As mentioned earlier, stroke is a major cardiovascular event with
a higher incidence among psoriasis population.47–50
It is accepted that inflammation plays a crucial role within
the complex pathophysiology of ischaemic stroke, particularly
in exacerbation of brain damage. When ischaemia occurs,
activation of microglia may result in secretion of both pro-
inflammatory CKs (from M1 phenotype, characterized by
high expression of IL-23 and IL-12) and neuroprotective
mediators (from M2 phenotype, characterized by high expres-
sion of IL-10).85 Other cells, like macrophages, infiltrate the
brain in the earlier phases of infarction, whilst neutrophils
and lymphocytes join in later phases.86 Likewise, activated
microglia is polarized to the M2 phenotype in the acute
phase, switching to M1 later, mainly in the ischaemic penum-
bra.85,87 IL-23 secreted from macrophages and DCs promotes
Figure 3 Scheme of involvement of Th17/IL-23 axis in psoriasis and cardiometabolic diseases. CAD, coronary artery disease; CV, car-
diovascular; CVR, cardiovascular risk; NAFLD, non-alcoholic fatty liver disease; NGF, nerve growth factor; PAD, peripheral artery disease;
PAI-1, plasminogen activator inhibitor-1; TIA, transient ischaemic attack; VEGF, vascular endothelial growth factor.. Yellow: CV diseases.
Green: Metabolic diseases.
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expansion of Th17 and cdT cells producing IL-17, contribut-
ing to post-stroke brain damage.88,89
The importance of this pathway has been observed in sev-
eral studies, which have shown elevations of the IL-23/IL-17
axis and IL-23R associated with worsening of neuron damage,
compared with controls in animal stroke models.86,87,90 In
humans, increased levels of IL-23 along with a markedly
increased proportion of IL-17A-producing cells and elevation
of IL-17A levels, as well as other CKs, have been identified at
several time points after stroke in comparison with con-
trols.91,92 Moreover, a positive correlation was found between
IL-23 levels and lesion volume.92 An increase of pro-inflam-
matory mediators occurred simultaneously with a decrease in
Treg cells and IL-10 levels,91 supporting the hypothesis of a
pro-inflammatory/anti-inflammatory imbalance as a mecha-
nism involved in stroke and brain damage. Results from a
study in mice are in line with this hypothesis, since
immunomodulation exerted by bone marrow stem cells
reduced IL-23 and IL-17 levels in serum and peri-infarcted
area.86
The effect of blocking IL-23/IL-17 has also been studied in
stroke models. Interestingly, IL-23 deficient animals showed sig-
nificantly lower levels of cdT cells, subsequent lower secretion of
IL-17 and a decreased infarct size.90 Similar results were
obtained after inhibition of IL-12/IL-23p40 subunit.93 Specific
suppression of IL-23p19 subunit resulted in lower levels of pro-
inflammatory IL-23 and IL-17 concurrent with upregulation of
the Treg transcription factor FoxP3. Blocking of p19 subunit
was, thus, associated with a less pronounced delayed phase of
cerebral ischaemia and reduced infarction and neurological
dysfunction.88
Peripheral artery disease
Lower limbs peripheral arterial disease (PAD) is a common syn-
drome among the adult population, mostly caused by
atherosclerosis. In psoriatic patients, a 98% higher risk of PAD
has been reported, compared with controls [OR: 1.98 (95% CI:
1.32–2.82)].94
Despite the scarce literature addressing the role of inflamma-
tion in PAD, the potential involvement of IL-23 in this disease
was assessed in a case-control study, which first showed a signifi-
cant increase of IL-23 levels in PAD patients compared with
controls.95
Hypertension
Data from epidemiological studies show that hypertension is
more prevalent among psoriasis patients [OR: 1.58 (95% CI:
1.42–1.76)], and prevalence is associated with psoriasis severity.1
Furthermore, psoriasis patients are prone to suffer difficult-to-
control hypertension, being 16.5 times and 19.9 times more
likely to require three- or four-drug treatment, respectively, than
non-psoriatic hypertensive patients.96
It is accepted that inflammation underlies the pathogenesis of
hypertension, and activated immune cells are critical factors
within this process.97–99 In particular, an involvement of IL-23/
IL-17 pathway has been evidenced in this field too.
T cells and macrophages accumulate in kidneys and perivas-
cular space. DCs are potent activators of T cells, which are
polarized towards Th17 differentiation due to secretion of IL-6,
TNF-a and IL-23 secretion and STAT3 phosphorylation and sig-
nalling. IL-17A produced by activated Th17 happened to be crit-
ical for vascular dysfunction and maintenance of
hypertension,99,100 and its production is increased in response to
angiotensin-II stimulus.101 It has been observed that increased
stretch of hypertensive arteries activates endothelium, releasing
IL-6, IL-23 and ROS whilst reducing nitric oxide (NO), and
favouring STAT3 activation.100 Studies have also showed that
isoketals (or isolevuglandins, derived from free radical-mediated
lipid peroxidation) accumulate in DCs in hypertension, promot-
ing cytokine production and being able to act as neoantigens
when adducted to proteins, activating DCs.98,99 These isoketal-
modified proteins have been found to be elevated in circulating
monocytes and DCs from hypertensive patients.98
Since an imbalance between Th17 and Treg is thought to
underlie, at least in part, the pathophysiology of CV disorders,
Liu et al.102 studied whether the use of common anti-
hypertensive and hypolipemiant drugs might have any effect on
this pathway. Patients treated with a combination of telmisartan
and rosuvastatin showed synergistic decrease of serum pro-
inflammatory components, including IL-23, Th17 cells and
IL-17A, as well as increase of anti-inflammatory components,
including Treg, FoxP3 and IL-10, and a reduction of carotid
intima-media thickness by ultrasound.102
Metabolic diseases and psoriasis: what is the
place for the IL-23/Th17 axis?
Overview
Metabolic disorders are more prevalent among patients with
psoriasis. Different meta-analyses found that psoriatic patients
have 27% higher risk of diabetes (RR: 1.27; 95% CI, 1.16–1.40)
and more than twofold risk of metabolic syndrome (OR: 2.26;
95% CI, 1.70–3.01). Indeed, psoriasis may act a as risk factor
for difficult-to-control diabetes. Conversely, metabolic disor-
ders may act as a risk factor for psoriasis development.1 Also,
obesity is more frequent among psoriatic patients (OR: 1.66;
95% CI: 1.46–1.89) and may be a negative factor for systemic
treatment response.1 A relationship between psoriasis severity
and obesity and metabolic syndrome has also been
observed.103,104 Non-alcoholic fatty liver disease (NAFLD), a
disorder associated with metabolic syndrome, has also been
shown to have a prevalence that is clearly higher among the
psoriatic population.105 Fig. 3 represents the relationship
between these diseases and psoriasis.
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Obesity
Obesity is a central feature associated with increased risk of
related metabolic dysfunction, including insulin resistance, dia-
betes, dyslipidaemia, hypertension and NAFLD, separately or
together comprising metabolic syndrome.106,107 In individuals
with body mass index (BMI) above 25 kg/m2, each 5 kg/m2
increase has been associated with 30% increase in overall mortal-
ity, 40% increase in CV mortality and 60% increase in diabetic
mortality.107 On the other hand, association between psoriasis
and obesity has been largely supported by evidence. Epidemio-
logical studies point to the risk of psoriasis being increased in
the obese population; further, the risk increases with increasing
BMI.108,109 Obesity may negatively affect systemic treatment of
psoriasis, including biologics; in psoriasis patients, a 12% (95%
CI: 1.01–1.24) increased risk of treatment interruption because
of lack of effectiveness and a 17% (95% CI: 1.02–1.36) increased
risk of adverse event occurrence has been associated with each
5 kg/m2 increase in BMI.110 Conversely, improved treatment
responses have been observed in patients after weight loss, with
improved outcomes in both clinical (PASI) and quality of life
(DLQI) variables.108
It is accepted that a close relationship between obesity and
chronic inflammation exists. Macrophages and T cells with pro-
inflammatory effects accumulate in adipose tissue whilst anti-
inflammatory Treg cells are diminished.111 T cells can interact
with DCs, regulating inflammatory response; in turn, adipose
tissue can secrete multiple molecules, including cytokines
(adipokines) with effects on inflammation signalling and
endothelial dysfunction.112,113 Interestingly, dysregulated levels
of adipokines in psoriasis patients have been reported, suggest-
ing these molecules may be a link between inflammation, obe-
sity, psoriasis and conditions improving CV risk.113
Due to the current consideration of obesity as a chronic low-
inflammation state, a potential involvement of the IL-23 path-
way in obesity has been investigated. In obese mice, an increased
level of DCs derived from adipose tissue (ATDCs) with an
immature phenotype has been found infiltrating adipose tissue.
These ATDCs secreted higher levels of IL-6, TGF-b and IL-23
than those DCs derived from spleen. Higher levels of IL-23p19
and IL-12/IL-23p40 mRNA, but not IL-12p35, were also demon-
strated. These findings suggest ATDCs promote Th17 differenti-
ation in adipose tissue, mediated by IL-23 and other CKs. This
hypothesis was tested by administering anti-IL-6 or anti-IL-23
antibodies, resulting in a reduction of Th17 cells.112 Consistent
results were observed in a study with obese women. Significantly
increased serum concentrations of IL-23, IL-17, as well as leptin
and macrophage migration inhibition factor (MIF), were evi-
denced, whilst IL-12 and IFN-c levels remained unchanged. No
correlation between IL-17 or IL-23 levels and leptin and MIF
were observed, which support an IL-23-dependent increase of
IL-17 in obese patients.114 Another study showed that obese
individuals0 intestine feature an increased jejunal mucosa surface
as well as increased total and intra-epithelial T-cell density.
Expression of IL-23, IFN-c, TGF-b and TNF-a were also
increased both in lamina propria and epithelium, as were IL-17A
levels, suggesting Th17 cells are expanded in obesity.111
Non-alcoholic fatty liver disease
Non-alcoholic fatty liver disease develops through a process of
fat deposition on liver cells, in an alcohol consumption non-
dependent way. Mild forms of this disorder include steatosis,
whilst severe forms are characterized by cell damage and include
steatohepatitis, potentially progressing to cirrhosis. NAFLD is
the leading cause of altered levels of hepatic enzymes in Western
countries, and considered as the hepatic manifestation of meta-
bolic syndrome. Prevalence of NAFLD is higher among patients
with metabolic syndrome and those with obesity; a correlation
between obesity severity and prevalence of NAFLD have been
established.105,115 The indolent development and subsequent
underdiagnosis of NAFLD contrast with the dramatic fact that
its aggressive form is the second most common cause of liver
transplantation in the USA.116
Non-alcoholic fatty liver disease is associated with psoriasis,
with a higher frequency observed among these patients.105
Gisondi et al. found NAFLD was present in 47% of patients with
plaque psoriasis, compared with a frequency of 28% in matched
healthy controls. Some biomarkers (IL-6, adiponectin) and PASI
score were higher in psoriasis patients with NAFLD than in
those without hepatic affectation.115 A later study found a simi-
lar prevalence (44% vs. 26%). In this study, both patients and
controls presenting NAFLD were scored with the NAFLD fibro-
sis score. Psoriatic patients obtained higher scoring and were at
higher risk of liver fibrosis than controls.117
The IL-23/Th17 pathway and an imbalance between pro- and
anti-inflammatory signalling seem to play a role in NAFLD as
well. Imbalanced levels of Th17/Treg has been demonstrated in
animal models. An increase in proportion of Th17 cells and
related cytokines IL-6, IL-23 and IL-17, and RORcs expression
along with a decrease in Treg cells and FoxP3 expression have
been identified in murine models118 but also in humans,119 and
suggest a pro-inflammatory predominance involved in the
pathogenesis of NAFLD. Likewise, an increase in Th17 cells and
related gene expression was observed in specimens of human liv-
ers affected with steatohepatitis.120 Some investigations using
monoclonal antibodies and other agents with an inhibitory effect
on Th17 differentiation have resulted in a decrease of Th17 and
pro-inflammatory molecules as well as reduced liver immune
cell infiltration, steatosis, and hepatic injury.119
Insulin resistance and diabetes mellitus
Psoriasis patients are at higher risk of diabetes mellitus (DM),
independently of other risk factors, and are more likely to
require pharmacological treatment for their diabetes mellitus.
Further, likelihood of insulin resistance and diabetic
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complications increase with psoriasis severity.1 Psoriasis patients
have triple risk [HR: 3.02 (95% CI: 2.42; 3.63)] of dying because
of endocrine, nutritional and metabolic disorders than controls,
independently of DM contribution to CV mortality.121 A gen-
ome-wide association study showed three different single-nucleo-
tide polymorphism, two of them located in the gene IL12B and 1
in the gene IL-23R, associated with between 2.7- and 5.9-fold
higher risk of developing DM2 in patients with psoriasis.122
Immune cells, including T cells and DCs, are acknowledged to
infiltrate pancreatic islets tissue, activating inflammatory and
autoimmune responses in type 1 DM that eventually result in
b-cells destruction.123 Evidence on IL-23 axis involvement has
been reported. In a preclinical study, it was observed that both
TGF-b + IL-6 and IL-23 + IL-6 can polarize na€ıve T cells to
IL-17-producing Th17. However, Th17 cells polarized in the
presence of IL-23 secreted larger amounts of IL-17, IL-22 and
expressed more IL-23R on their surface, compared with those
polarized in the presence of TGF-b. When these cells were
injected into non-obese diabetic mice, all animals developed dia-
betes. On the contrary, TGF-b-polarized cells showed a Treg
phenotype with significantly higher secretion of IL-10; interest-
ingly, these cells did not induce DM when injected into mice.124
This study suggest a diabetogenic potential for the IL-23/Th17
axis and raises again the hypothesis of a Th17/Treg imbalance
dependent on a predominant CK milieu.
Consistent with animal investigations, the involvement of the
IL-23/Th17 pathway in diabetic humans has also been reported.
Fatima et al.125 found that IL-23 and IL-17A, among other pro-
inflammatory cytokines were significantly upregulated in type 1
diabetic patients, exhibiting a relationship with age and gly-
caemia and suggesting a synergistic interaction of IL-23, IL-17A
and TNF-a in b-cells damage. Similarly, a later study showed an
age-dependent increase of IL-23 mRNA and augmented levels of
IL-17A and IL-22, among other CKs, in type 2 diabetic patients,
confirming a role in DM onset.126
Conclusions
The IL-23/Th17 axis has a prominent role in pathophysiology of
psoriasis, in which the upregulation of this pathway, together
with other inflammatory cytokines (e.g. TNF and type I IFN),
contributes to develop a ‘pro-inflammatory state’ in psoriasis
patients. A growing body of recent evidence suggests inflamma-
tion, through multiple mediators and pathways, is mechanisti-
cally involved in most of cardiac and metabolic chronic diseases,
including obesity and non-alcoholic fat liver, known common
psoriasis associated conditions. Here, we have reviewed the evi-
dence on the IL-23/Th17 pathway and suggest its upregulation
(in addition to detrimental lifestyle) is a potential root of many
cardiometabolic psoriasis comorbidity. This overlapping has also
led to the hypothesis that highly specific monoclonal antibodies
developed for systemic treatment of psoriasis might have an
effect on the progression of its comorbidity, although at this
stage the standard-of-care for psoriasis comorbidity is essential
too and further evidence is needed to confirm or refute this sup-
position.
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